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Grade≥2 toxicity, there were 3 and 1 patient with pneumonitis Grades 2 and 3, respectively; one patient had Grade 2 diarrhea;
and one patient experienced Grade 3 lower gastrointestinal hemorrhage. On univariate analysis, having a longer time from the
primary tumor diagnosis date to the oligometastasis was associated with lower risk of mortality (P=0.03). In contrast, the lack
of complete/partial response (P=0.04) or having a greater oligometastasis size (HR=4.5; P=0.01) was associated with higher risk
of mortality. On multivariate analysis, only the response to the HT retained signiﬁcance (P=0.01).
Conclusions. Hypofractionated image-guided HT is well tolerated and offers adequate local control with low acute morbidity in
patients with extracraneal oligometastatic disease. We found that the response to HT was the only predictor for OS.
http://dx.doi.org/10.1016/j.rpor.2013.03.556
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Introduction. Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very
high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of
technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality
is safe and effective in both early stage primary cancer and oligometastases.
Objective. We present our experience in the treatment of primary and metastatic tumors with SBRT.
Methods. BetweenApril 2012 andFebruary 2013, 22 patientswith 24different locationsunderwent SBRT for primary andmetastatic
tumors using CT and/or PET-CT for diagnosis. Treatment was made using vacuum body ﬁxation and abdominal compression (in
some cases) to reduce intrafractional organ motion. We made three planning CTs in all patients: free breathing, inhalation and
exhalation. Internal target volume (ITV) was delineated based on fusion of three CTs. Planning target volume (PTV) was then
determined by adding additional setup margin to ITV. The locations of the treatments were distributed as follows: 11 primary
lung tumors, 6 lung metastases, 3 adrenal metastasis, 3 lymph node metastasis and 1 vertebral metastases. We have made
different fraction schemes, from 12Gy in 5 fractions (60Gy) until 4Gy in 10 fractions (40Gy).
Results. The acute toxicity has been excellent, appearing only G1 pneumonitis. Assessment of response was performed with CT
and/or PET-CT, with a 80% of local control.
Conclusions. SBRT is a treatment option for many inoperable patients with primary and metastatic tumors and provides a great
beneﬁt, because of its high efﬁciency, with a control of lesions in more than 85% of cases, and excellent clinical tolerance due to
lowest toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.557
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Purpose. We have analyzed our experience with stereotactic body radiation therapy (SBRT) in lung tumors. We have determined
our treatment accuracy using Bodyﬁx® as immobilization system and conebeam CT (CBCT) for image guidance, and the set-up
and treatment times using different planning systems.
Methods and materials. We have studied the patients treated from August 2011 to December 2012. Every patient underwent
4DCT after immobilization with Bodyﬁx®. We contoured the internal target volume (ITV) and we created a planning tar-
get volume (PTV) with a 5mm expansion. A stereotactic RT plan was designed using 7–9 coplanar and noncoplanar ﬁelds,
dynamic arcs or a combination of both of them. Before each fraction a CBCT was made for image guidance. We have mea-
sured the set-up time (total time in treatment room minus beam-on time) and the treatment time (beam-on time), comparing
the length of treatment between different RT plans. We have made CBCT after treatment to study the intrafraction tumor
movements.
Results. Eighteen patients have been treated. Nine patients were treated with ﬁxed ﬁelds, seven with dynamic arcs and two with
a combination of arcs and ﬁelds. Mean times for treatment were 10.4min, 4.3min and 4min, respectively, being arc-therapy
signiﬁcantly faster than ﬁxed ﬁelds treatment (p=0.006). First fraction set-up mean time was 35.7min, signiﬁcantly longer than
overall set-up mean time, that was 27.8min (p<0.05). The mean intrafraction tumor motion was 0.2 cm (0–0.4) in AP, 0.2 cm
(0.1–0.5) in SI and 0.2 cm (0–0.5) in ML direction.
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Conclusion. Treatment time is a factor that could inﬂuence on SBRT uncertainty. In our experience, set-up time is longer the ﬁrst
day of treatment than in the rest of fractions. Dynamic arc therapy is faster than treatment with only ﬁxed ﬁelds. Immobilization
with Bodyﬁx® gives enough accuracy, being our PTV margin of 0.5 cm appropriate according to our data.
http://dx.doi.org/10.1016/j.rpor.2013.03.558
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Purpose. To analyze our experience treating lung tumours with stereotactic body radiation therapy (SBRT), emphasising what
concerns to toxicity.
Materials and methods. We evaluate our results treating patients with stage I lung cancer or lung metastases with SBRT from
August 2011 to December 2012. We describe toxicity using the Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
We evaluate the local control (LC), regional relapse (RR), distant progression (DP) and overall survival (OS).
Results. We have treated eighteen patients in that period with a median age of 74 (54–87). 22% were women and 78% men. The
ECOG performance status was 1 in 72% patients, 2 in 22% and 3 in 5%. Thirteen patients had stage I lung cancer (72%) and ﬁve had
lung metastases (28%). With a median follow up of 6.5 months, 6 patients developed grade 1 pneumonitis (33%) and 2 patients
grade 2 pneumonitis (11%). Two patients had grade 1 chest wall pain. Only one grade 1 dermatitis was observed. The LC was of
100%. Between patients with stage I lung cancer, RR was observed in 6% and DP in 13%. OS was 89%.
Conclusions. With a short median follow-up time our results are coherent with published data, achieving excellent local control
with distant progression as ﬁrst relapse in patients diagnosed of stage I lung cancer. SBRT was well tolerated with no severe
toxicity observed.
http://dx.doi.org/10.1016/j.rpor.2013.03.559
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Background. Stereotactic radiosurgery (SRS) delivers a potent, highly focused dose of radiation to the tumor while sparing the
surrounding normal tissues.
Aim. The purpose of this study is to assess the outcome of patients with intracranial meningiomas treated with SRS.
Methods. A total of 73 patients with 221 benign meningiomas treated with SRS and followed up for more than a year were reviewed
between 1991 and 2005. Fifty patients (68%) were treated with SRS to the primary meningioma while 23 (32%) patients received
SRS to the relapses adjacent or distant from the site of the initial meningioma that was previously treated with surgery alone.
Mean tumor margin dose was 14Gy (range, 10–16). SRS was delivered after surgery in 117 meningiomas (55 patients).
Results. The median age at diagnosis was 47 years old (range, 16–74) and the median follow-up 5.8 years (range, 1–13.6). The 3-
and 5-year overall survival rates for all patients were 95% and 90%, respectively. The mean gross tumor volume decreased from
4.17 cm3 to 3.23 cm3 after SRS (P=0.057). Twenty-two (10%) meningiomas increased after SRS. In addition, clinical symptoms
improved in 36% and remained stable in 45%. With regard to morbidity of SRS, only 7 patients (9.6%) had late complications,
including: edema (N=4), brain necrosis (N=4), gliosis (N=1), and paresis of the III pair (N=1). There was no treatment-related
mortality.
Conclusions. SRS for patients with multiple intracranial meningiomas is effective yielding a high local tumor control, whereas the
treatment-related morbidity remains low.
http://dx.doi.org/10.1016/j.rpor.2013.03.560
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Introduction. Whole-brain radiation therapy (WBRT) combined with boost on the metastases has demonstrated to improve the
results of the treatment in selected patients in contrast to single WBRT.
